| # | Drug | Count |
|---|---|---|
| 0 | INFLIXIMAB | 8 |
| 1 | PREDNISONE | 5 |
| 2 | RITUXIMAB | 5 |
| 3 | ADALIMUMAB | 4 |
| 4 | CYCLOPHOSPHAMIDE | 4 |
| 5 | CYCLOPHOSPHAMIDE FOR INJECTION | 4 |
| 6 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 4 |
| 7 | TACROLIMUS | 4 |
| 8 | CISPLATIN | 3 |
| 9 | ERGOCALCIFEROL | 3 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | EPCORITAMAB-BYSP | 1 | 0.0007 |
| 1 | IBRITUMOMAB TIUXETAN | 1 | 0.0007 |
| 2 | RIZATRIPTAN BENZOATE | 2 | 0.0002 |
| 3 | OBINUTUZUMAB | 3 | 0.0002 |
| 4 | MITOXANTRONE HYDROCHLORIDE | 1 | 0.0002 |
| 5 | LIDOCAINE PATCH 5% | 1 | 0.0001 |
| 6 | ATOVAQUONE | 1 | 0.0001 |
| 7 | LUBIPROSTONE | 1 | 0.0001 |
| 8 | ERGOCALCIFEROL | 3 | 0.0001 |
| 9 | TIMOLOL MALEATE | 1 | 0.0001 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |
| 1 | Chloride Channel Activator [EPC] | 1 | 0.0001 |
| 2 | Provitamin D2 Compound [EPC] | 3 | 0.0001 |
| 3 | Antimalarial [EPC] | 1 | 0.0001 |
| 4 | Antiprotozoal [EPC] | 1 | 0.0001 |
| 5 | Interleukin-23 Antagonist [EPC] | 3 | 0.0000 |
| 6 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 1 | 0.0000 |
| 7 | Interleukin-12 Antagonist [EPC] | 2 | 0.0000 |
| 8 | CD20-directed Cytolytic Antibody [EPC] | 6 | 0.0000 |
| 9 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 2 | 0.0000 |